Search

Displaying results 851 - 860 of 4539 in total
  1. Drug

    Bromodiphenhydramine

    go.drugbank.com/drugs/DB01237
    Approved

    Bromodiphenhydramine is an ethanolamine antihistamine with antimicrobial property. Bromodiphenhydramine is used in the control of cutaneous allergies. Ethanolamine antihistamines produce marked sedation in most patients.

  2. Drug

    Modified vaccinia ankara

    go.drugbank.com/drugs/DB15483
    ApprovedInvestigational

    Modified Vaccinia Ankara (MVA) refers to an attenuated strain of the Vaccinia virus. Vaccines using MVA are live and non-replicating, and are produced using Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN).

  3. Drug

    Sonidegib

    go.drugbank.com/drugs/DB09143
    ApprovedInvestigational

    Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.

  4. Drug

    Selumetinib

    go.drugbank.com/drugs/DB11689
    ApprovedInvestigational

    Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the prob...

  5. Drug

    Amifostine

    go.drugbank.com/drugs/DB01143
    ApprovedInvestigational

    A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.

  6. Drug

    Defactinib

    go.drugbank.com/drugs/DB12282
    ApprovedInvestigational

    [L53208,A273943] Defactinib was approved by the US FDA in May 2025 in a co-package alongside [avutometinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian

  7. Drug

    Nitazoxanide

    go.drugbank.com/drugs/DB00507
    ApprovedInvestigationalVet approved

    of illnesses caused by other protozoa or helminths [A31976]. … Nitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment

  8. Drug

    Coagulation factor X human

    go.drugbank.com/drugs/DB13148
    ApprovedInvestigational

    Inherited factor X deficiency is a rare autosomal recessive bleeding disorder that is estimated to occur in 1:1 000 000 individuals up to 1:500 carriers [A31471]. … Coagulation Factor X (Human), is a plasma-derived human blood coagulation factor is used by adults and children (aged 12 years and above) with hereditary Factor X deficiency.

  9. Drug

    Venetoclax

    go.drugbank.com/drugs/DB11581
    ApprovedInvestigational

    Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label].

  10. Drug

    Leridistim

    go.drugbank.com/drugs/DB15095
    Investigational

    Leridistim is under investigation in clinical trial NCT00004215 (Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia).